Home
Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. Market Share Analysis for November 2025

REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PRODUCT PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >> KEY PROGRAMS Cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL, including diffuse large B-cell lymphoma (DLBCL) ALLO-316: ccRCC ALLO-329: autoimmune disease EXPLORE OUR PIPELINE >> LEADERSHIP A […]

Health > Biotechnology and Pharmaceuticals

Domainallogene.com

Year Founded2017

Employees201 - 500

Annual Revenue$25M - $50M

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (including company regionals)

allogene.com

See more website traffic and engagement information

Allogene Therapeutics, Inc. Revenue up to November 2025 is 25M - 50M

revenue generated by Allogene Therapeutics, Inc. top domains

Allogene Therapeutics, Inc. top domains revenue over 3 years

Revenue for Allogene Therapeutics, Inc. top domains

allogene.com25M - 50M

See more with Sales Intelligence

Total visits to Allogene Therapeutics, Inc.'s top domains

Understand Allogene Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

allogene.com16.1K

See more with Sales Intelligence

Avg. visit duration in Allogene Therapeutics, Inc.'s top domains

Analyze Allogene Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

allogene.com00:00:45

See more with Sales Intelligence

Avg. pageviews on Allogene Therapeutics, Inc.'s top domains

See how Allogene Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

allogene.com2.10

See more with Sales Intelligence

Allogene Therapeutics, Inc. top competitors by domain

Top similar sites in November 2025, ranked by their affinity

assemblybio.comCompany NameAssembly Biosciences, Inc.Employees51 - 200HQUnited States, California, San FranciscoAnnual revenue$25M - $50MTotal visits5.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Allogene Therapeutics, Inc.

These are the website technologies, by industry, used by Allogene Therapeutics, Inc. top domains

Advertising (8)

PubMatic

Payment & Currencies (8)

Cart Functionality

Social (4)

Instagram

Widget (4)

Twemoji

More Technologies

12

See all

News & Signals from Allogene Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAllogene Therapeutics Inc attends event ASH Annual Meeting.Allogene Therapeutics announces ALPHA3 Trial-in-Progress poster presentation at ASH Annual Meeting.

NewsAllogene Therapeutics Inc attends event 2025 Biopharma Back to School Summit.Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T(TM) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.

NewsDavid D. Chang leaves Allogene Therapeutics Inc as President, Chief Executive Officer & Director.Dr. David D. Chang is a President, Chief Executive Officer & Director at Allogene Therapeutics, Inc., a Director & Venture Partner at Vida Ventures LLC, a Venture Partner at Two River Consulting LLC, a Board Observer at Cell Design Labs, Inc., a Venture Partner at Two River Group Holdings LLC and a Venture Partner at VV Manager LLC.